Dyslipidemia in patients with chronic and end-stage kidney disease
- PMID: 24454313
- PMCID: PMC3884190
- DOI: 10.1159/000351985
Dyslipidemia in patients with chronic and end-stage kidney disease
Abstract
In this review, we discuss the physiology, diagnosis and treatment of dyslipidemia in patients with chronic and end-stage renal disease. The recent important clinical trials in patients with chronic kidney disease and dyslipidemia are reviewed. Because of the lack of evidence in treating lipid abnormalities in this specific patient population, we propose that future studies should focus on the pathophysiological mechanisms and treatment of dyslipidemia in this special patient population.
Keywords: Chronic kidney disease; Dyslipidemia; End-stage renal disease; Oxidized low-density lipoprotein.
References
-
- Coresh J, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12. - PubMed
-
- Foley RN, et al. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 suppl 3):S112–S119. - PubMed
-
- Go AS, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305. - PubMed
-
- Ruilope LM, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001;12:218–225. - PubMed
-
- Hebert PR, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278:313–321. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources